Cargando…

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma

Detalles Bibliográficos
Autores principales:	Nix, Nancy M., Braun, Kirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093460/ https://www.ncbi.nlm.nih.gov/pubmed/25032033

Ejemplares similares

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
por: Colombo, Joshua R, et al.
Publicado: (2014)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
por: Hart, Christopher D, et al.
Publicado: (2013)

Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
por: Schlumberger, M, et al.
Publicado: (2017)

Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes
por: Roof, Logan, et al.
Publicado: (2023)

Metastatic medullary thyroid carcinoma: a new way forward
por: Angelousi, Anna, et al.
Publicado: (2022)

The treatment landscape in thyroid cancer: a focus on cabozantinib
por: Weitzman, Steven P, et al.
Publicado: (2015)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer
por: Capdevila, Jaume, et al.
Publicado: (2022)

Metastatic medullary thyroid carcinoma: A case report
por: Niafar, Mitra, et al.
Publicado: (2011)

Medullary Thyroid Carcinoma Presenting as Metastatic Disease to the Breast
por: Kanteti, Archana P., et al.
Publicado: (2020)

Medullary thyroid carcinoma (MTC): unusual metastatic sites
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
por: Kraeber–Bodéré, F., et al.
Publicado: (2009)

Hypercalcitoninemia is not Pathognomonic of Medullary Thyroid Carcinoma
por: Toledo, Sergio PA, et al.
Publicado: (2009)

Metastatic medullary thyroid carcinoma presenting as ectopic Cushing’s syndrome
por: Forde, Hannah E, et al.
Publicado: (2021)

Medullary Thyroid Carcinoma: An Update on Imaging
por: Kushchayev, Sergiy V., et al.
Publicado: (2019)

Thyroid: Medullary Carcinoma
por: Somnay, Yash R., et al.
Publicado: (2013)

Molecular and Other Novel Advances in Treatment of Metastatic Epithelial and Medullary Thyroid Cancers
por: Tai, David, et al.
Publicado: (2010)

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
por: Ito, Yasuhiro, et al.
Publicado: (2017)

Kinase inhibitors for advanced medullary thyroid carcinoma
por: Schlumberger, Martin, et al.
Publicado: (2012)

Management of medullary carcinoma of the thyroid: a review
por: Jayasinghe, Ravindri, et al.
Publicado: (2022)

Treatment of advanced medullary thyroid cancer
por: Smit, Johannes
Publicado: (2013)

Pediatric Medullary Thyroid Carcinoma
por: Starenki, Dmytro, et al.
Publicado: (2015)

PET Imaging in Recurrent Medullary Thyroid Carcinoma
por: Treglia, Giorgio, et al.
Publicado: (2012)

Recent Updates on the Management of Medullary Thyroid Carcinoma
por: Kim, Bo Hyun, et al.
Publicado: (2016)

Current Guidelines for Management of Medullary Thyroid Carcinoma
por: Kim, Mijin, et al.
Publicado: (2021)

Medullary carcinoma of the thyroid gland.
por: Russell, C.
Publicado: (1980)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model
por: Yun, Hyeok-Jun, et al.
Publicado: (2022)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Medullary carcinoma of the thyroid: an update
por: Alevizaki, Maria
Publicado: (2013)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Medullary carcinoma of the thyroid metastatic to the breast: a case report and literature review
por: Martins, Sebastião Nunes, et al.
Publicado: (2014)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h0thihphm7h1mf3kh0rerjau3b